Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod: two case reports.
Vulvitis circumscripta plasmacellularis (VCP) is a rare but well-described entity. It is notorious for its recalcitrant nature to various modalities of treatment. Intralesional interferon-alpha showed some promise, with complete resolution, but is coupled with the side-effect of myelosuppression. Topical imiquimod is a novel immune response modifier with the ability to induce the production of interferon-alpha. In this paper, we report two cases of VCP whose lesions were resistant to antibiotics, topical and oral corticosteroids, but resolved after a treatment trial with imiquimod.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000287:Administration, Topical; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008875:Middle Aged; D014847:Vulvitis / Q000188:drug therapy* / Q000473:pathology
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000077271:Imiquimod